A recent study published in the Journal of Thoracic Disease presents data confirming CyberKnife® as a safe and effective treatment option for patients with metastatic lung cancer.
The study evaluated the efficacy and tolerability of CyberKnife for 95 patients with lung metastases. A total of 134 metastatic lung tumors were treated with stereotactic body radiation therapy (SBRT) using CyberKnife technology to observe local control and long-term survival and toxicity.
Over a period of three years, follow-ups with patients resulted in a 97.6% local control rate at the one-year mark, 90.6% at two-years and 87% at three-years. Median survival time was 38 months and median progression-free survival was 14 months. The two-year progression-free rate was 29% and overall survival was 61.3%. An overview of the study is available here.
Oklahoma CyberKnife treats primary and metastatic lung tumors with CyberKnife SBRT. Treatment does not require surgery or sedation and is completed in five or fewer outpatient sessions. If you have been diagnosed with metastatic lung cancer, contact Oklahoma CyberKnife to schedule a consultation and learn whether you may be a candidate for CyberKnife treatment.
This is not intended as medical advice to replace the expertise and judgment of your health care team. It is intended to help you and your family make informed decisions, together with your doctor.